Evidence map›Paper›PMID 31887199›Full record

Observational studyPloS one2019

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.

Sarah Burkill, Pia Vattulainen, Yvonne Geissbuehler, Meritxell Sabido Espin, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, Kjell-Morten Myhr and 4 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah BurkillCentre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8988-4724
Pia VattulainenEPID research, Helsinki, Finland.
Yvonne GeissbuehlerNovartis Pharma AG, Basel, Switzerland.
Meritxell Sabido EspinMerck group, Darmstadt, Germany.
Catrinel PopescuBiogen, Maidenhead, United Kingdom.
Kiliana Suzart-WoischnikBayer AG, Berlin, Germany.
Jan HillertDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Miia ArtamaNational Institute for Health and Welfare, Helsinki, Finland.
Auli Verkkoniemi-AholaDepartment of Neurology, Helsinki University, Helsinki, Finland.
Kjell-Morten MyhrDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Sven CnattingiusDivision of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Pasi KorhonenEPID research, Helsinki, Finland.
Scott MontgomeryDivision of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Shahram BahmanyarCentre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large scale study of a population of MS women is therefore warranted.

objectivesTo assess whether, among those born to women with MS, infants prenatally exposed to IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally exposed to any MS disease modifying drugs.

methodsSwedish and Finnish register data was used. Births to women with MS in Sweden and Finland between 2005-2014 for which a birth measurement for weight, height, and head circumference was available were included. The exposure window was from 6 months prior to LMP to the end of pregnancy.

resultsIn Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure window, and 835 pregnancies were counted as unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331 respectively. Infants prenatally exposed to interferon-beta were on average 28 grams heavier (p = 0.17), 0.01 cm longer (p = 0.95), and had head circumferences 0.14 cm larger (p = 0.13) in Sweden. In Finland, infants were 50 grams lighter (p = 0.27), 0.02 cm shorter (p = 0.92) and had head circumferences 0.22 cm smaller (p = 0.15) relative to those unexposed.

conclusionsThis study provides evidence that exposure to IFN-beta during pregnancy does not influence birth weight, length, or head circumference.

Indexed as

AdultBirth WeightBody HeightFemaleFinlandHumansInfant, NewbornInterferon-betaMaternal-Fetal ExchangeMultiple SclerosisPregnancyPregnancy ComplicationsRegistriesSwedenInterferon-beta

Identifiers

PMID31887199
PMCPMC6936848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.